SKYWORKS SOLUTIONS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SKYWORKS SOLUTIONS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $4.09B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $4.18B | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $4.77B | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $5.49B | Nov 15, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $4.09B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $4.18B | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $4.77B | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $5.49B | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $5.11B | Nov 17, 2023 |
| FY2020 | Oct 2, 2020 | $956.80M | Nov 17, 2020 |
| FY2020 | Jun 26, 2020 | $736.80M | Nov 17, 2020 |
| FY2020 | Mar 27, 2020 | $766.10M | Nov 17, 2020 |
| FY2020 | Dec 27, 2019 | $896.10M | Nov 17, 2020 |
| FY2020 | Sep 27, 2019 | $827.40M | Nov 17, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 28, 2018 | $1.01B | Nov 15, 2018 |
| FY2018 | Jun 29, 2018 | $894.30M | Nov 15, 2018 |
| FY2018 | Mar 30, 2018 | $913.40M | Nov 15, 2018 |
| FY2018 | Dec 29, 2017 | $1.05B | Nov 15, 2018 |
| FY2018 | Sep 29, 2017 | $984.60M | Nov 15, 2018 |
| FY2018 | Jun 30, 2017 | $900.80M | Nov 15, 2018 |
| FY2018 | Mar 31, 2017 | $851.70M | Nov 15, 2018 |
| FY2018 | Dec 30, 2016 | $914.30M | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $835.40M | Nov 13, 2017 |
| FY2017 | Jul 1, 2016 | $751.70M | Nov 13, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $1.68B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $1.72B | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $2.11B | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $2.60B | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $2.51B | Nov 17, 2023 |
| FY2020 | Oct 2, 2020 | $458.90M | Nov 17, 2020 |
| FY2020 | Jun 26, 2020 | $334.10M | Nov 17, 2020 |
| FY2020 | Mar 27, 2020 | $375.60M | Nov 17, 2020 |
| FY2020 | Dec 27, 2019 | $444.30M | Nov 17, 2020 |
| FY2020 | Sep 27, 2019 | $406.00M | Nov 17, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $477.10M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $596.00M | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $982.80M | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $1.28B | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $1.50B | Nov 17, 2023 |
| FY2020 | Oct 2, 2020 | $246.90M | Nov 17, 2020 |
| FY2020 | Jun 26, 2020 | $129.70M | Nov 17, 2020 |
| FY2020 | Mar 27, 2020 | $181.10M | Nov 17, 2020 |
| FY2020 | Dec 27, 2019 | $257.10M | Nov 17, 2020 |
| FY2020 | Sep 27, 2019 | $210.60M | Nov 17, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $500.00M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $637.40M | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $1.13B | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $1.53B | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $1.61B | Nov 17, 2023 |
| FY2022 | Oct 2, 2020 | $891.80M | Nov 23, 2022 |
| FY2021 | Sep 27, 2019 | $952.00M | Nov 24, 2021 |
| FY2020 | Sep 28, 2018 | $1.32B | Nov 17, 2020 |
| FY2019 | Sep 29, 2017 | $1.25B | Nov 14, 2019 |
| FY2018 | Sep 30, 2016 | $1.12B | Nov 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $785.50M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $631.70M | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $606.80M | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $617.90M | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $532.30M | Nov 17, 2023 |
| FY2022 | Oct 2, 2020 | $464.10M | Nov 23, 2022 |
| FY2021 | Sep 27, 2019 | $424.10M | Nov 24, 2021 |
| FY2020 | Sep 28, 2018 | $404.50M | Nov 17, 2020 |
| FY2019 | Sep 29, 2017 | $355.20M | Nov 14, 2019 |
| FY2018 | Sep 30, 2016 | $312.40M | Nov 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $371.50M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $300.80M | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $314.00M | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $329.80M | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $322.50M | Nov 17, 2023 |
| FY2022 | Oct 2, 2020 | $231.40M | Nov 23, 2022 |
| FY2021 | Sep 27, 2019 | $198.30M | Nov 24, 2021 |
| FY2020 | Sep 28, 2018 | $207.80M | Nov 17, 2020 |
| FY2019 | Sep 29, 2017 | $204.60M | Nov 14, 2019 |
| FY2018 | Sep 30, 2016 | $195.90M | Nov 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $1.30B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $1.82B | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $1.86B | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $1.42B | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $1.77B | Nov 17, 2023 |
| FY2022 | Oct 2, 2020 | $1.20B | Nov 23, 2022 |
| FY2021 | Sep 27, 2019 | $1.37B | Nov 24, 2021 |
| FY2020 | Sep 28, 2018 | $1.26B | Nov 17, 2020 |
| FY2019 | Sep 29, 2017 | $1.46B | Nov 14, 2019 |
| FY2012 | Sep 28, 2012 | $285.24M | Nov 21, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $195.00M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $157.00M | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $210.30M | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | $489.40M | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | $637.80M | Nov 17, 2023 |
| FY2022 | Oct 2, 2020 | $389.40M | Nov 23, 2022 |
| FY2021 | Sep 27, 2019 | $398.40M | Nov 24, 2021 |
| FY2020 | Sep 28, 2018 | $422.30M | Nov 17, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $7.92B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $8.28B | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $8.43B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $8.87B | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | $8.59B | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | $5.11B | Nov 24, 2021 |
| FY2020 | Sep 27, 2019 | $4.84B | Nov 17, 2020 |
| FY2019 | Sep 28, 2018 | $4.83B | Nov 14, 2019 |
| FY2018 | Sep 29, 2017 | $4.57B | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $3.86B | Nov 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $2.16B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $1.95B | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $2.34B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $3.40B | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | $3.29B | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | $942.50M | Nov 24, 2021 |
| FY2020 | Sep 27, 2019 | $717.30M | Nov 17, 2020 |
| FY2019 | Sep 28, 2018 | $731.90M | Nov 14, 2019 |
| FY2018 | Sep 29, 2017 | $507.90M | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $314.00M | Nov 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $5.76B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $6.34B | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | $6.08B | Nov 7, 2025 |
| FY2025 | Sep 30, 2022 | $5.47B | Nov 7, 2025 |
| FY2024 | Oct 1, 2021 | $5.30B | Nov 15, 2024 |
| FY2023 | Oct 2, 2020 | $4.16B | Nov 17, 2023 |
| FY2022 | Sep 27, 2019 | $4.12B | Nov 23, 2022 |
| FY2021 | Sep 28, 2018 | $4.10B | Nov 24, 2021 |
| FY2020 | Sep 29, 2017 | $4.07B | Nov 17, 2020 |
| FY2019 | Sep 30, 2016 | $3.54B | Nov 14, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $2.18B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $2.18B | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $2.18B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $2.18B | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | $2.18B | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | $1.19B | Nov 24, 2021 |
| FY2020 | Sep 27, 2019 | $1.19B | Nov 17, 2020 |
| FY2019 | Sep 28, 2018 | $1.19B | Nov 14, 2019 |
| FY2018 | Aug 17, 2018 | $306.80M | Nov 15, 2018 |
| FY2018 | Sep 29, 2017 | $883.00M | Nov 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $5.66B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $6.03B | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $5.88B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $5.42B | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | $5.19B | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | $4.82B | Nov 24, 2021 |
| FY2020 | Sep 27, 2019 | $4.31B | Nov 17, 2020 |
| FY2019 | Sep 28, 2018 | $3.73B | Nov 14, 2019 |
| FY2018 | Sep 29, 2017 | $3.06B | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $2.26B | Nov 13, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $1.16B | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $1.37B | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $718.80M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $566.00M | Nov 17, 2023 |
| FY2023 | Oct 1, 2021 | $882.90M | Nov 17, 2023 |
| FY2023 | Oct 2, 2020 | $566.70M | Nov 17, 2023 |
| FY2022 | Sep 27, 2019 | $851.30M | Nov 23, 2022 |
| FY2021 | Sep 28, 2018 | $733.30M | Nov 24, 2021 |
| FY2020 | Sep 29, 2017 | $1.62B | Nov 17, 2020 |
| FY2017 | Sep 30, 2016 | $1.08B | Nov 13, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $496.40M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $994.30M | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $992.90M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $1.69B | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | $2.24B | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | $0 | Nov 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 3 | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | 3 | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | 6 | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | 7 | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | 9 | Nov 17, 2023 |
| FY2020 | Oct 2, 2020 | 1 | Nov 17, 2020 |
| FY2020 | Jun 26, 2020 | 0 | Nov 17, 2020 |
| FY2020 | Mar 27, 2020 | 1 | Nov 17, 2020 |
| FY2020 | Dec 27, 2019 | 1 | Nov 17, 2020 |
| FY2020 | Sep 27, 2019 | 1 | Nov 17, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 3 | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | 3 | Nov 7, 2025 |
| FY2025 | Sep 29, 2023 | 6 | Nov 7, 2025 |
| FY2024 | Sep 30, 2022 | 7 | Nov 15, 2024 |
| FY2023 | Oct 1, 2021 | 8 | Nov 17, 2023 |
| FY2020 | Oct 2, 2020 | 1 | Nov 17, 2020 |
| FY2020 | Jun 26, 2020 | 0 | Nov 17, 2020 |
| FY2020 | Mar 27, 2020 | 1 | Nov 17, 2020 |
| FY2020 | Dec 27, 2019 | 1 | Nov 17, 2020 |
| FY2020 | Sep 27, 2019 | 1 | Nov 17, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 148.70M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | 159.90M | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | 159.50M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | 160.20M | Nov 17, 2023 |
| FY2022 | Oct 1, 2021 | 165.30M | Nov 23, 2022 |
| FY2021 | Oct 2, 2020 | 165.60M | Nov 24, 2021 |
| FY2020 | Sep 27, 2019 | 170.10M | Nov 17, 2020 |
| FY2019 | Sep 28, 2018 | 177.40M | Nov 14, 2019 |
| FY2018 | Sep 29, 2017 | 183.10M | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | 184.90M | Nov 13, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $105.60M | Nov 7, 2025 |
| FY2025 | Jun 27, 2025 | $103.90M | Nov 7, 2025 |
| FY2025 | Mar 28, 2025 | $110.60M | Nov 7, 2025 |
| FY2025 | Dec 27, 2024 | $112.50M | Nov 7, 2025 |
| FY2025 | Sep 27, 2024 | $112.00M | Nov 7, 2025 |
| FY2025 | Jun 28, 2024 | $109.10M | Nov 7, 2025 |
| FY2025 | Mar 29, 2024 | $109.10M | Nov 7, 2025 |
| FY2025 | Dec 29, 2023 | $108.90M | Nov 7, 2025 |
| FY2024 | Sep 29, 2023 | $108.50M | Nov 15, 2024 |
| FY2024 | Jun 30, 2023 | $98.70M | Nov 15, 2024 |